USPTO Examiner BORI IBRAHIM D - Art Unit 1629

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18945317GLABRIDIN COMPOSITION WITH HIGH SKIN PERMEABILITY, AND PREPARATION METHOD AND USE THEREOFNovember 2024February 2025Allow300YesNo
18892208KRAS MODULATORS AND USES THEREOFSeptember 2024March 2025Allow610YesNo
18761559DEUTERATED ORGANIC COMPOUNDS AND USES THEREOFJuly 2024March 2025Allow810YesNo
18611026METHOD FOR PRODUCING 1,3-DIOLEIN FROM BIOMASSMarch 2024August 2024Allow500YesNo
18580809Reduced Odor Formaldehyde-Containing Antiseptic LotionJanuary 2024June 2025Allow1700YesNo
18506944TREATMENT OF CARDIOPULMONARY DISORDERSNovember 2023April 2024Allow500YesNo
183855358-(4-BROMOBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023April 2024Allow510YesNo
183858024,4'-NAPHTHALENE-1,5-DIYLBIS(DIAZENE-2,1-DIYL)DIPHENOL AS AN ANTIOXIDANT COMPOUNDOctober 2023April 2024Allow610NoNo
18497653PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMAOctober 2023April 2025Allow1810NoNo
18371095SELECTIVE COX-2 INHIBITION OF 2-(SUBSTITUTED BENZYL)-3,5,6,7-TETRAHYDRO-4H-CYCLOPENTA[4,5]THIENO[2,3-d]PYRIMIDIN-4-ONES AND 4-FLUORO-N-(4-OXO-3,5,6,7-TETRAHYDRO-4H-CYCLOPENTA[4,5]THIENO[2,3-d]PYRIMIDIN-2-YL)BENZAMIDE AS ANTI-INFLAMMATORY AGENTSSeptember 2023October 2024Allow1340YesNo
18192210Methods And Compositions For The Treatment Of CancerMarch 2023October 2024Allow1910NoNo
18026250NEAR-INFRARED NANO-PHOTOSENSITIZER, AND PREPARATION METHOD AND USE THEREOFMarch 2023October 2023Allow700YesNo
18176962TREATING EXTRAPYRAMIDAL SYNDROME USING TRAPIDILMarch 2023December 2024Allow2110NoNo
18107162METHOD FOR INDUCING TUMOR REGRESSIONFebruary 2023February 2025Allow2410NoNo
18101986FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTSJanuary 2023December 2024Allow2310NoNo
17945311OINTMENTS FOR TREATING DRY SKINSeptember 2022April 2025Allow3110NoNo
17882949COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERSAugust 2022February 2025Abandon3010NoNo
17874621COMPOUNDS FOR TREATING BRAIN CANCERJuly 2022March 2025Allow3120NoNo
17867370AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFENJuly 2022May 2024Allow2210NoNo
17826602Aqueous Nebulization CompositionMay 2022February 2025Allow3220NoNo
17752676METHOD FOR INDUCING TUMOR REGRESSIONMay 2022November 2024Allow3010NoNo
17752648Hybrid Mycelial Cellulose Sheet and Preparation ThereofMay 2022February 2023Allow921YesNo
17750969COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATIONMay 2022April 2025Abandon3520NoNo
17744224USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYMay 2022March 2024Allow2310NoNo
17662866METHOD FOR TREATING INFLAMMATORY DISORDERSMay 2022May 2024Allow2420NoNo
17724589Compounds And Compositions As Protein Kinase InhibitorsApril 2022August 2023Allow1600NoNo
17723163COMPOUNDS FOR TREATING HUNTINGTON'S DISEASEApril 2022March 2025Allow3521YesNo
17588033PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VEJanuary 2022May 2024Allow2810YesNo
17627967PYRAZOLO[3,4-D]PYRROLO[1,2-B]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORSJanuary 2022February 2025Allow3700YesNo
17572493COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENTJanuary 2022February 2025Allow3720NoNo
17538749METHODS OF USING DIPIVEFRINNovember 2021September 2024Abandon3310NoNo
17534817COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATIONNovember 2021December 2023Abandon2410NoNo
17528510COMBINATION THERAPIES FOR THE TREATMENT OF CANCERNovember 2021April 2023Allow1600YesNo
17528959COMPOSITIONS, USES AND METHODS FOR TREATMENT OF INFERTILITY AND SUBFERTILITYNovember 2021July 2024Abandon3210NoNo
17529078Pharmaceutical CompositionNovember 2021July 2024Abandon3210NoNo
17515800PEPTIDE FOR TREATING SEPSIS DERIVED FROM Rv2626c PROTEIN OF MYCOBACTERIUM TUBERCULOSISNovember 2021September 2024Allow3411YesNo
17510572MIXTURES OF SABADILLA ALKALOIDS AND DIAMIDES AND USES THEREOFOctober 2021June 2024Abandon3101NoNo
17502899AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFENOctober 2021February 2022Allow410YesNo
17484921Combination Therapy for Male Sexual DysfunctionSeptember 2021May 2025Abandon4420YesNo
17479649DOSAGE REGIMEN FOR A S1P RECEPTOR AGONISTSeptember 2021October 2024Abandon3620NoNo
17460693NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODSAugust 2021February 2025Allow4210YesNo
17404579Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and UsesAugust 2021January 2025Allow4111NoNo
17398622SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2BAugust 2021July 2024Allow3520NoNo
17379083METHOD FOR PRODUCING GLYCERIDES OF HYDROXYCARBOXYLIC ACIDSJuly 2021February 2025Allow4311YesNo
17374488TOPICAL TREATMENT OF WOUNDS WITH STATINS AND CHOLESTEROL FOR SCAR REDUCTIONJuly 2021September 2023Allow2611YesNo
17365886Method of Treatment for Ketamine InfusionJuly 2021February 2023Abandon2020YesNo
17415966Intranasal FormulationJune 2021March 2025Allow4520NoNo
17296568AN ANTIMICROBIAL COMPOSITIONMay 2021November 2024Allow4210NoNo
17309216N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODSMay 2021February 2024Allow3400NoNo
17314647BUPROPION AS A MODULATOR OF DRUG ACTIVITYMay 2021March 2022Abandon1020YesNo
17290224SOLID DISPERSIONS FOR TREATMENT OF CANCERApril 2021May 2025Abandon4930NoNo
17246143GLYCOSIDASE INHIBITORSApril 2021May 2024Allow3611NoNo
17234574PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODSApril 2021February 2022Allow910YesNo
17229561METHOD OF TREATMENTApril 2021February 2024Abandon3420NoNo
17225472Body SculptingApril 2021August 2023Abandon2810NoNo
17222953Method and Composition for Enhancing the Quality and Benefits of SleepApril 2021May 2025Allow4930YesNo
17220515METHODS OF TREATING DEPRESSION WITH VORTIOXETINEApril 2021September 2023Abandon3010NoNo
17218814COMPOSITION CONTAINING ECTOINE OR HYDROXYECTOINE AS AN ACTIVE SUBSTANCE FOR PROMOTING THE REGENERATION OF INJURED BODY TISSUEMarch 2021January 2025Abandon4530NoNo
17219733BOWEL CLEANSING COMPOSITIONMarch 2021September 2023Abandon2940YesNo
17215466ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITSMarch 2021December 2024Allow4421YesYes
17209078COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENTMarch 2021September 2023Allow3010YesNo
17206362Salts of ZuclomipheneMarch 2021October 2023Abandon3110NoNo
17203467FORMULATIONS AND METHODS RELATED TO EYE IRRITATIONMarch 2021July 2024Allow4031NoNo
17168876PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMAFebruary 2021July 2023Allow3020NoNo
17166927SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAMEFebruary 2021February 2024Abandon3620YesNo
17258610B-CELL IMMUNOTHERAPY IN CANCER TREATMENTJanuary 2021April 2025Allow5120YesNo
17123380THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USEDecember 2020August 2024Abandon4421NoNo
17121567PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTERDecember 2020June 2023Abandon3001NoNo
17117559ANTICOAGULANT REVERSAL AGENTSDecember 2020December 2023Abandon3711NoNo
17111288FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTSDecember 2020January 2023Allow2510NoNo
15734537BUSULFAN COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFDecember 2020December 2024Abandon4821NoNo
17100789METHOD OF PREPARING KRILL OIL AND KRILL OIL COMPOSITIONNovember 2020April 2024Allow4121YesNo
17055856BIOCOMPATIBLE ADHESIVE MATERIALS WITH IONIC AND COVALENT INTERACTIONNovember 2020April 2024Abandon4110NoNo
17096500COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITYNovember 2020April 2023Abandon2910NoNo
17075764TOPICAL CANNABINOID COMPOSITIONS FOR CLEAR SKINOctober 2020March 2025Allow5231NoNo
17075551SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERSOctober 2020May 2024Abandon4201NoNo
17072994USE OF OXYGENATED CHOLESTEROL SULFATES (OCS) TO TREAT INFLAMMATORY SKIN DISEASE AND SKIN LESIONSOctober 2020June 2024Abandon4411NoNo
17069453THERAPEUTIC USES OF GLP1R AGONISTSOctober 2020January 2025Abandon5120NoNo
17064517ANTICONVULSANT ACTIVITY OF STEROIDSOctober 2020February 2024Abandon4121NoNo
17035293METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERSeptember 2020January 2023Allow2701YesNo
17030068METHOD FOR INDUCING TUMOR REGRESSIONSeptember 2020January 2023Allow2850YesNo
17017988NOVEL PEDIATRIC COMBINATIONSeptember 2020August 2021Allow1120YesNo
17000567COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOFAugust 2020April 2023Abandon3110NoNo
16998918USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSISAugust 2020April 2023Abandon3210NoNo
16931272ABUSE RESISTANT TRANSMUCOSAL DRUG DELIVERY DEVICEJuly 2020March 2024Abandon4410NoNo
16919440USE OF ERYTHRITOL OR COMPOSITIONS COMPRISING SAME AS MAMMAL-SAFE INSECTICIDESJuly 2020July 2023Abandon3631YesNo
16915660COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIAJune 2020December 2021Allow1810NoNo
16893018USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYJune 2020February 2022Allow2010NoNo
16768892Substituted 3,4,12,12a-Tetrahydro-1H-[1,4]Oxazino[3,4-c]Pyrido[2,1-f][1,2,4]Triazine-6,8-dione, Pharmaceutical Composition, Method for the Production and Use ThereofJune 2020April 2024Allow4740NoNo
16871135COMBINATION OF FUROSEMIDE AND STEROIDS AND APPLICATION SYSTEM THEREFORMay 2020September 2023Abandon4011NoNo
16858990PLATELET-DERIVED GROWTH FACTOR RECEPTOR MUTATIONS AND COMPOSITIONS AND METHODS RELATING THERETOApril 2020September 2023Abandon4111NoNo
16857934MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENTApril 2020March 2023Allow3511YesNo
16857523COMPOSITIONS COMPRISING SORBITAN CARBOXYLIC ESTERS AND GLYCEROL CARBOXYLIC ESTERSApril 2020September 2022Allow2801YesNo
16849727METHODS FOR ASSESSING RESPONSIVENESS TO ASTHMA TREATMENT BASED ON VNN-1 EXPRESSION AND PROMOTER METHYLATIONApril 2020September 2024Abandon5350YesNo
16753482PROCESSING METHOD FOR BIOPOLYMERS USING SOLVENT COMBINATIONSApril 2020July 2024Allow5141YesNo
16827503COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITYMarch 2020September 2020Allow620YesNo
16647715COMPOSITIONS, USES AND METHODS FOR TREATMENT OF INFERTILITY AND SUBFERTILITYMarch 2020February 2022Allow2311YesNo
16647001COMPOSITION FOR SKIN EXTERNAL APPLICATIONMarch 2020March 2021Allow1210NoNo
16805821THERAPEUTICAL METHODS, FORMULATIONS AND NUTRACEUTICAL FORMULATIONSMarch 2020November 2022Allow3311NoNo
16801567Methods of Treating HyperalgesiaFebruary 2020July 2022Abandon2801NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BORI, IBRAHIM D.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
9
(64.3%)
Examiner Reversed
5
(35.7%)
Reversal Percentile
55.9%
Higher than average

What This Means

With a 35.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
55
Allowed After Appeal Filing
8
(14.5%)
Not Allowed After Appeal Filing
47
(85.5%)
Filing Benefit Percentile
15.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BORI, IBRAHIM D - Prosecution Strategy Guide

Executive Summary

Examiner BORI, IBRAHIM D works in Art Unit 1629 and has examined 677 patent applications in our dataset. With an allowance rate of 45.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner BORI, IBRAHIM D's allowance rate of 45.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BORI, IBRAHIM D receive 2.16 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BORI, IBRAHIM D is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +45.2% benefit to allowance rate for applications examined by BORI, IBRAHIM D. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.5% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 21.3% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 77.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.8% of appeals filed. This is in the 28% percentile among all examiners. Of these withdrawals, 65.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 72.4% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.